The effectiveness and safety of topical brepocitinib for the treatment of mild‐to‐moderate atopic dermatitis

Brepocitinib is an experimental topical cream that is applied to areas of the skin affected by AD, however, it has not been approved for sale yet. Brepocitinib works by blocking two enzymes called TYK2 and JAK1, and reducing the production of chemical signals from the immune system believed to cause AD. The main purpose of this study was to explore the effect of different doses of brepocitinib on AD, as well as the effect of once or twice daily treatment. The patients were also monitored for any medical problems they had while in the study.